MoodNCT04935099
The Effects of a Single Dose of Wild Blueberries on Mood and Cognition in Healthy Young Adults
A study testing Wild blueberry powder in people with Mood and Affect, run by University of Reading at 1 site in United Kingdom.
Trial summary
This study aims to investigate whether consuming a drink containing powdered blueberries (equivalent to 150 g fresh fruit) can improve mood and cognition in healthy young adults. Read more about this study
- Who is it for?
- Ages 18 to 25 yearsHealthy volunteers can take part
- What is being tested?
- Wild blueberry powder
- Type of treatment
- Vaccines
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 33 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 26 May 2021to 27 Aug 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 25 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- 18 to 25 years of age
- Willingness to provide blood samples
Who cannot join
- Allergy to blueberries or any other Vaccinium species
- Diagnosis or symptoms of anxiety, depression, or other mental health conditions
- Any medically significant condition (e.g. anemia, gastrointestinal disorders, diabetes)
- Use of psychoactive medication or recreational drugs in the last two weeks
- Current use of medication that could interact with the intervention (e.g. antibiotics)
- Obesity or underweight
- Participation in other interventional studies in the last month
- Pregnancy or lactation
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
School of Psychology and Clinical Languages, University of Reading
Reading, Berkshire, RG6 6AL
About this study
Official title: The Effects of a Single Dose of Wild Blueberries on Mood and Cognition in Healthy Young Adults: a Randomized, Double-blind, Placebo-controlled, Crossover Study
This study aims to investigate whether consuming a drink containing powdered blueberries (equivalent to 150 g fresh fruit) can improve mood and cognition in healthy young adults. Blood biomarkers of inflammation and neurotransmitter turnover will be analyzed as well as responses to computer-based cognitive tasks designed to measure verbal memory, executive function, and emotional processing.
Read the detailed description
The present study will examine the psychological effects of a single dose of freeze-dried wild blueberries using a randomized, double-blind, placebo-controlled, counterbalanced, crossover design. A total of 30 healthy young adults will consume two drinks: one containing 22 g blueberry powder and the other containing 22 g matched placebo powder in counterbalanced order one week apart. The investigators will assess changes in transient mood, cognitive-emotional function, and serum biomarkers of inflammation, neuroplasticity, and monoamine metabolism from baseline to 2 hours post-ingestion.
- Being tested
- Wild blueberry powder, Placebo powder
- Keywords
- blueberry, anthocyanins, flavonoids
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Wild blueberry powderDietary supplement
22 g freeze-dried wild blueberry (Vaccinium angustifolium) powder, mixed with 250 ml water, and served in an opaque container.
Placebo powderDietary supplement
22 g placebo powder matched for macronutrients and flavor, mixed with 250 ml water, and served in an opaque container.
| Study group | Role | What they receive |
|---|---|---|
| Blueberry/Placebo | Experimental | In this arm, participants will receive the blueberry intervention first, followed by the placebo one week later. Receives: Dietary Supplement: Wild blueberry powder; Dietary Supplement: Placebo powder |
| Placebo/Blueberry | Experimental | In this arm, participants will receive the placebo first, followed by the blueberry intervention one week later. Receives: Dietary Supplement: Wild blueberry powder; Dietary Supplement: Placebo powder |
What is being measured
The primary outcome is the main question the study is designed to answer.
Global transient mood as measured by PANAS-X
The Positive and Negative Affect Schedule - Expanded Form (PANAS-X) is a validated, self-rated measure of affective state, encompassing two general dimensions (positive and negative affect). These will be calculated separately by adding the values of the individual items (21 positive and 25 negative items). Thus, the scales will range from 0 to 84 points for positive affect and from 0 to 100 for negative affect, with a higher score indicating greater positive or negative affect. Positive affect will be considered the primary measure.
Measured: baseline
Global transient mood as measured by PANAS-X
The Positive and Negative Affect Schedule - Expanded Form (PANAS-X) is a validated, self-rated measure of affective state, encompassing two general dimensions (positive and negative affect). These will be calculated separately by adding the values of the individual items (21 positive and 25 negative items). Thus, the scales will range from 0 to 84 points for positive affect and from 0 to 100 for negative affect, with a higher score indicating greater positive or negative affect. Positive affect will be considered the primary measure
Measured: 2 hours post-ingestion
Negative interpretation bias
A negative interpretation bias is defined as a tendency to interpret ambiguous information in a consistently threatening or negative manner, thus serving as an objective indicator of affective state. In this task, participants will be asked to categorize facial expressions of anger, happiness, and surprise as either positive or negative. Interpretation bias will be operationalized as the percent of trials in which surprised faces were rated as negative, out of the total number of surprise trials (48 trials).
Measured: baseline
Negative interpretation bias
A negative interpretation bias is defined as a tendency to interpret ambiguous information in a consistently threatening or negative manner, thus serving as an objective indicator of affective state. In this task, participants will be asked to categorize facial expressions of anger, happiness, and surprise as either positive or negative. Interpretation bias will be operationalized as the percent of trials in which surprised faces were rated as negative, out of the total number of surprise trials (48 trials).
Measured: 2 hours post-ingestion
Cognitive flexibility (accuracy on post-switch trials)
A task-switching test will be used to assess cognitive performance when switching between two predictable tasks requiring simple numerical decisions. The main outcome of interest is the average accuracy of responses to post-switch trials (those immediately following a switch to a new task).
Measured: baseline
Cognitive flexibility (accuracy on post-switch trials)
A task-switching test will be used to assess cognitive performance when switching between two predictable tasks requiring simple numerical decisions. The main outcome of interest is the average accuracy of responses to post-switch trials (those immediately following a switch to a new task).
Measured: 2 hours post-ingestion
Delayed verbal memory on RAVLT
The Rey Auditory Verbal Learning Test (RAVLT) is a standard neuropsychological assessment designed to evaluate verbal memory. The participant hears a list of 15 words and is asked to recall as many words as possible. This procedure is repeated five times. The main outcome of interest is the number of correctly recalled words 20 minutes after the last presentation of the list of words (Trial A7).
Measured: baseline
Delayed verbal memory on RAVLT
The Rey Auditory Verbal Learning Test (RAVLT) is a standard neuropsychological assessment designed to evaluate verbal memory. The participant hears a list of 15 words and is asked to recall as many words as possible. This procedure is repeated five times. The main outcome of interest is the number of correctly recalled words 20 minutes after the last presentation of the list of words (Trial A7).
Measured: 2 hours post-ingestion
Serum brain-derived neurotrophic factor (BDNF)
Serum levels of BDNF will be analyzed using enzyme-linked immunosorbent assay (ELISA).
Measured: baseline
Serum brain-derived neurotrophic factor (BDNF)
Serum levels of BDNF will be analyzed using enzyme-linked immunosorbent assay (ELISA).
Measured: 2 hours post-ingestion
Secondary outcomes (34)
Distinct affective states as measured by PANAS-X subscales
The following affective states will be examined separately as defined by the PANAS-X subscales: Joviality (Happiness), Self-Assurance, Attentiveness, Fatigue, Serenity. Higher scores will indicate greater intensity of the respective affective state.
Measured: baseline
Distinct affective states as measured by PANAS-X subscales
The following affective states will be examined separately as defined by the PANAS-X subscales: Joviality (Happiness), Self-Assurance, Attentiveness, Fatigue, Serenity. Higher scores will indicate greater intensity of the respective affective state.
Measured: 2 hours post-ingestion
Reaction time to positive stimuli
The average reaction time to correctly categorized happy faces in the facial expression task.
Measured: baseline
Reaction time to positive stimuli
The average reaction time to correctly categorized happy faces in the facial expression task.
Measured: 2 hours post-ingestion
Reaction time to negative stimuli
The average reaction time to correctly categorized angry faces in the facial expression task.
Measured: baseline
Reaction time to negative stimuli
The average reaction time to correctly categorized angry faces in the facial expression task.
Measured: 2 hours post-ingestion
Attentional bias to emotional information
Attentional bias to emotional information will be operationalized as the average reaction time to correctly categorized angry faces divided by the average reaction time to correctly categorized happy faces. Thus, a higher value indicates a tendency to attend to and process positive information over negative information.
Measured: baseline
Attentional bias to emotional information
Attentional bias to emotional information will be operationalized as the average reaction time to correctly categorized angry faces divided by the average reaction time to correctly categorized happy faces. Thus, a higher value indicates a tendency to attend to and process positive information over negative information.
Measured: 2 hours post-ingestion
Cognitive flexibility (accuracy on remaining trials of task-switching test)
The average accuracy (in %) of responses to the remaining trials of the task-switching test will be measured as a secondary outcome. In this task, participants have to switch between two predictable tasks requiring simple numerical decisions.
Measured: baseline
Cognitive flexibility (accuracy on remaining trials of task-switching test)
The average accuracy (in %) of responses to the remaining trials of the task-switching test will be measured as a secondary outcome. In this task, participants have to switch between two predictable tasks requiring simple numerical decisions.
Measured: 2 hours post-ingestion
Choice reaction time (post-switch trials)
The average reaction time of correct responses to post-switch trials of the task-switching test.
Measured: baseline
Choice reaction time (post-switch trials)
The average reaction time of correct responses to post-switch trials of the task-switching test.
Measured: 2 hours post-ingestion
Choice reaction time (remaining trials of task-switching test)
The average reaction time of correct responses to remaining trials of the task-switching test.
Measured: baseline
Choice reaction time (remaining trials of task-switching test)
The average reaction time of correct responses to remaining trials of the task-switching test.
Measured: 2 hours post-ingestion
Final acquisition on RAVLT (Trial 5)
The number of correctly retrieved words on Trial 5 (List A) of the Rey Auditory Verbal Learning Test.
Measured: baseline
Final acquisition on RAVLT (Trial 5)
The number of correctly retrieved words on Trial 5 (List A) of the Rey Auditory Verbal Learning Test.
Measured: 2 hours post-ingestion
Recall of interference list on RAVLT
The number of correctly retrieved words from the interference list (List B) of the Rey Auditory Verbal Learning Test.
Measured: baseline
Recall of interference list on RAVLT
The number of correctly retrieved words from the interference list (List B) of the Rey Auditory Verbal Learning Test.
Measured: 2 hours post-ingestion
Immediate recall on RAVLT
The number of correctly recalled words on the Rey Auditory Verbal Learning Test 2 minutes after the final presentation of List A (and following the presentation and recall of List B).
Measured: baseline
Immediate recall on RAVLT
The number of correctly recalled words on the Rey Auditory Verbal Learning Test 2 minutes after the final presentation of List A (and following the presentation and recall of List B).
Measured: 2 hours post-ingestion
Proactive interference on RAVLT
Proactive interference on the Rey Auditory Verbal Learning Test is defined as the number of correctly recalled words from the interference List B divided by the number of correctly recalled words on Trial 1 of List A (B1/A1). A higher score indicates less proactive interference.
Measured: baseline
Proactive interference on RAVLT
Proactive interference on the Rey Auditory Verbal Learning Test is defined as the number of correctly recalled words from the interference List B divided by the number of correctly recalled words on Trial 1 of List A (B1/A1). A higher score indicates less proactive interference.
Measured: 2 hours post-ingestion
Retroactive interference on RAVLT
Retroactive interference on the Rey Auditory Verbal Learning Test is defined as the number of correctly recalled words on Trial 6 of List A (the free recall trial after the interference List B) divided by the number of correctly recalled words on Trial 5 of List A (A6/A5). A higher score indicates less retroactive interference.
Measured: baseline
Retroactive interference on RAVLT
Retroactive interference on the Rey Auditory Verbal Learning Test is defined as the number of correctly recalled words on Trial 6 of List A (the free recall trial after the interference List B) divided by the number of correctly recalled words on Trial 5 of List A (A6/A5). A higher score indicates less retroactive interference.
Measured: 2 hours post-ingestion
Retention on RAVLT
Retention on the Rey Auditory Verbal Learning Test is defined as the number of correctly recalled words on Trial 7 of List A (the delayed recall trial at 20 minutes) divided by the number of correctly retrieved words on Trial 6 of List A (A7/A6). Thus, a higher score indicates a higher retention rate.
Measured: baseline
Retention on RAVLT
Retention on the Rey Auditory Verbal Learning Test is defined as the number of correctly recalled words on Trial 7 of List A (the delayed recall trial at 20 minutes) divided by the number of correctly retrieved words on Trial 6 of List A (A7/A6). Thus, a higher score indicates a higher retention rate.
Measured: 2 hours post-ingestion
Serum monoamine oxidase B (MAO-B) inhibition
The activity of the enzyme MAO-B in serum will be analyzed using a fluorometric assay.
Measured: baseline
Serum monoamine oxidase B (MAO-B) inhibition
The activity of the enzyme MAO-B in serum will be analyzed using a fluorometric assay.
Measured: 2 hours post-ingestion
Serum 3,4-dihydroxyphenylglycol (DHPG)
Serum levels of DHPG will be analyzed using liquid chromatography-mass spectrometry (LS-MS) to indirectly determine monoamine oxidase A (MAO-A) activity.
Measured: baseline
Serum 3,4-dihydroxyphenylglycol (DHPG)
Serum levels of DHPG will be analyzed using liquid chromatography-mass spectrometry (LS-MS) to indirectly determine monoamine oxidase A (MAO-A) activity.
Measured: 2 hours post-ingestion
Serum interleukin-6 (IL-6)
Serum levels of IL-6 will be analyzed using enzyme-linked immunosorbent assay (ELISA) as an indication of systemic inflammation.
Measured: baseline
Serum interleukin-6 (IL-6)
Serum levels of IL-6 will be analyzed using enzyme-linked immunosorbent assay (ELISA) as an indication of systemic inflammation.
Measured: 2 hours post-ingestion
Serum C-reactive protein (CRP)
Serum levels of CRP will be analyzed using enzyme-linked immunosorbent assay (ELISA) as an indication of systemic inflammation.
Measured: baseline
Serum C-reactive protein (CRP)
Serum levels of CRP will be analyzed using enzyme-linked immunosorbent assay (ELISA) as an indication of systemic inflammation.
Measured: 2 hours post-ingestion
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jun 2021
- Study start26 May 2021
- Primary completion27 Aug 2021
- Study completion27 Aug 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for MoodStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 33 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Reading
- Sponsor type
- University, hospital or other
- Collaborators
- Wild Blueberry Association of North America
- Responsible party
- Principal investigator, Prof Claire Williams, University of Reading
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04935099
- Sponsor's protocol ID
- 21/09
- Status last verified
- Sep 2021
- First submitted
- 27 May 2021
- Last updated
- 21 Sep 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 21 Sep 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effects of a Single Dose of Wild Blueberries on Mood and Cognition in Healthy Young Adults: a Randomized, Double-blind, Placebo-controlled, Crossover Study
- ClinicalTrials.gov ID
- NCT04935099
- Acronym / sponsor ID
- 21/09
- Keywords
- blueberry, anthocyanins, flavonoids
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 33 participants (actual)
- Lead sponsor
- University of ReadingUniversity, hospital or other
- Collaborators
- Wild Blueberry Association of North America
- Study start
- 26 May 2021 (actual)
- Primary completion
- 27 Aug 2021 (actual)
- Study completion
- 27 Aug 2021 (actual)
- First posted
- 22 Jun 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to investigate whether consuming a drink containing powdered blueberries (equivalent to 150 g fresh fruit) can improve mood and cognition in healthy young adults. Blood biomarkers of inflammation and neurotransmitter turnover will be analyzed as well as responses to computer-based cognitive tasks designed to measure verbal memory, executive function, and emotional processing.
Detailed description
The present study will examine the psychological effects of a single dose of freeze-dried wild blueberries using a randomized, double-blind, placebo-controlled, counterbalanced, crossover design. A total of 30 healthy young adults will consume two drinks: one containing 22 g blueberry powder and the other containing 22 g matched placebo powder in counterbalanced order one week apart. The investigators will assess changes in transient mood, cognitive-emotional function, and serum biomarkers of inflammation, neuroplasticity, and monoamine metabolism from baseline to 2 hours post-ingestion.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Blueberry/Placebo | Experimental | Dietary Supplement: Wild blueberry powder, Dietary Supplement: Placebo powderIn this arm, participants will receive the blueberry intervention first, followed by the placebo one week later. |
| Placebo/Blueberry | Experimental | Dietary Supplement: Wild blueberry powder, Dietary Supplement: Placebo powderIn this arm, participants will receive the placebo first, followed by the blueberry intervention one week later. |
Who may qualify
- Ages
- 18 to 25 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- 18 to 25 years of age
- Willingness to provide blood samples
Key exclusion criteria (8 listed)
- Allergy to blueberries or any other Vaccinium species
- Diagnosis or symptoms of anxiety, depression, or other mental health conditions
- Any medically significant condition (e.g. anemia, gastrointestinal disorders, diabetes)
- Use of psychoactive medication or recreational drugs in the last two weeks
- Current use of medication that could interact with the intervention (e.g. antibiotics)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Wild blueberry powder22 g freeze-dried wild blueberry (Vaccinium angustifolium) powder, mixed with 250 ml water, and served in an opaque container. | Dietary supplement | Blueberry/Placebo, Placebo/Blueberry |
| Placebo powder22 g placebo powder matched for macronutrients and flavor, mixed with 250 ml water, and served in an opaque container. | Dietary supplement | Blueberry/Placebo, Placebo/Blueberry |
Primary outcome
Global transient mood as measured by PANAS-X
Time frame: baseline
The Positive and Negative Affect Schedule - Expanded Form (PANAS-X) is a validated, self-rated measure of affective state, encompassing two general dimensions (positive and negative affect). These will be calculated separately by adding the values of the individual items (21 positive and 25 negative items). Thus, the scales will range from 0 to 84 points for positive affect and from 0 to 100 for negative affect, with a higher score indicating greater positive or negative affect. Positive affect will be considered the primary measure.
Global transient mood as measured by PANAS-X
Time frame: 2 hours post-ingestion
The Positive and Negative Affect Schedule - Expanded Form (PANAS-X) is a validated, self-rated measure of affective state, encompassing two general dimensions (positive and negative affect). These will be calculated separately by adding the values of the individual items (21 positive and 25 negative items). Thus, the scales will range from 0 to 84 points for positive affect and from 0 to 100 for negative affect, with a higher score indicating greater positive or negative affect. Positive affect will be considered the primary measure
Negative interpretation bias
Time frame: baseline
A negative interpretation bias is defined as a tendency to interpret ambiguous information in a consistently threatening or negative manner, thus serving as an objective indicator of affective state. In this task, participants will be asked to categorize facial expressions of anger, happiness, and surprise as either positive or negative. Interpretation bias will be operationalized as the percent of trials in which surprised faces were rated as negative, out of the total number of surprise trials (48 trials).
Negative interpretation bias
Time frame: 2 hours post-ingestion
A negative interpretation bias is defined as a tendency to interpret ambiguous information in a consistently threatening or negative manner, thus serving as an objective indicator of affective state. In this task, participants will be asked to categorize facial expressions of anger, happiness, and surprise as either positive or negative. Interpretation bias will be operationalized as the percent of trials in which surprised faces were rated as negative, out of the total number of surprise trials (48 trials).
Cognitive flexibility (accuracy on post-switch trials)
Time frame: baseline
A task-switching test will be used to assess cognitive performance when switching between two predictable tasks requiring simple numerical decisions. The main outcome of interest is the average accuracy of responses to post-switch trials (those immediately following a switch to a new task).
Cognitive flexibility (accuracy on post-switch trials)
Time frame: 2 hours post-ingestion
A task-switching test will be used to assess cognitive performance when switching between two predictable tasks requiring simple numerical decisions. The main outcome of interest is the average accuracy of responses to post-switch trials (those immediately following a switch to a new task).
Delayed verbal memory on RAVLT
Time frame: baseline
The Rey Auditory Verbal Learning Test (RAVLT) is a standard neuropsychological assessment designed to evaluate verbal memory. The participant hears a list of 15 words and is asked to recall as many words as possible. This procedure is repeated five times. The main outcome of interest is the number of correctly recalled words 20 minutes after the last presentation of the list of words (Trial A7).
Delayed verbal memory on RAVLT
Time frame: 2 hours post-ingestion
The Rey Auditory Verbal Learning Test (RAVLT) is a standard neuropsychological assessment designed to evaluate verbal memory. The participant hears a list of 15 words and is asked to recall as many words as possible. This procedure is repeated five times. The main outcome of interest is the number of correctly recalled words 20 minutes after the last presentation of the list of words (Trial A7).
Serum brain-derived neurotrophic factor (BDNF)
Time frame: baseline
Serum levels of BDNF will be analyzed using enzyme-linked immunosorbent assay (ELISA).
Serum brain-derived neurotrophic factor (BDNF)
Time frame: 2 hours post-ingestion
Serum levels of BDNF will be analyzed using enzyme-linked immunosorbent assay (ELISA).
34 secondary outcomes
Distinct affective states as measured by PANAS-X subscales
Time frame: baseline
Distinct affective states as measured by PANAS-X subscales
Time frame: 2 hours post-ingestion
Reaction time to positive stimuli
Time frame: baseline
Reaction time to positive stimuli
Time frame: 2 hours post-ingestion
Reaction time to negative stimuli
Time frame: baseline
Reaction time to negative stimuli
Time frame: 2 hours post-ingestion
Attentional bias to emotional information
Time frame: baseline
Attentional bias to emotional information
Time frame: 2 hours post-ingestion
Cognitive flexibility (accuracy on remaining trials of task-switching test)
Time frame: baseline
Cognitive flexibility (accuracy on remaining trials of task-switching test)
Time frame: 2 hours post-ingestion
Choice reaction time (post-switch trials)
Time frame: baseline
Choice reaction time (post-switch trials)
Time frame: 2 hours post-ingestion
Choice reaction time (remaining trials of task-switching test)
Time frame: baseline
Choice reaction time (remaining trials of task-switching test)
Time frame: 2 hours post-ingestion
Final acquisition on RAVLT (Trial 5)
Time frame: baseline
Final acquisition on RAVLT (Trial 5)
Time frame: 2 hours post-ingestion
Recall of interference list on RAVLT
Time frame: baseline
Recall of interference list on RAVLT
Time frame: 2 hours post-ingestion
Immediate recall on RAVLT
Time frame: baseline
Immediate recall on RAVLT
Time frame: 2 hours post-ingestion
Proactive interference on RAVLT
Time frame: baseline
Proactive interference on RAVLT
Time frame: 2 hours post-ingestion
Retroactive interference on RAVLT
Time frame: baseline
Retroactive interference on RAVLT
Time frame: 2 hours post-ingestion
Retention on RAVLT
Time frame: baseline
Retention on RAVLT
Time frame: 2 hours post-ingestion
Serum monoamine oxidase B (MAO-B) inhibition
Time frame: baseline
Serum monoamine oxidase B (MAO-B) inhibition
Time frame: 2 hours post-ingestion
Serum 3,4-dihydroxyphenylglycol (DHPG)
Time frame: baseline
Serum 3,4-dihydroxyphenylglycol (DHPG)
Time frame: 2 hours post-ingestion
Serum interleukin-6 (IL-6)
Time frame: baseline
Serum interleukin-6 (IL-6)
Time frame: 2 hours post-ingestion
Serum C-reactive protein (CRP)
Time frame: baseline
Serum C-reactive protein (CRP)
Time frame: 2 hours post-ingestion
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Sep 2021.
- Individual participant dataSharing planned: Yes
Related trials for Mood
Recruiting
Unified Protocol in Penitentiary Facilities
Depression Disorders, Anxiety
Not yet recruiting
Preventive and Personalized Digital Emotion Regulation Skills Intervention to Reduce Depression and Anxiety in Youths With Adverse Childhood Experiences
Adverse Childhood Experience, Depression / Major Depressive Disorder
RecruitingPhase 4
Biomarker-Guided Antidepressant Selection
Depression - Major Depressive Disorder, Treatment-resistant Depression (TRD)
Recruiting
Targeting Network Dysfunction in Apathy of Late-life Depression Using Digital Therapeutics
Major Depressive Disorder, Apathy
RecruitingObservational study
Psychotherapy for Irritability in Youth: Comparing Active Treatment to Nonactive Psychoeducation Supportive Psychotherapy
Irritability, Disruptive Mood Dysregulation Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Wild blueberry powder in people with Mood and Affect, run by University of Reading at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Sep 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Global transient mood as measured by PANAS-X (time frame: baseline). The study lists 10 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Sep 2021.